AstraZeneca Makes Case For Independence With $23 Bil. Pipeline Potential
This article was originally published in The Pink Sheet Daily
The U.K. drug maker went on the offense against Pfizer’s hostile takeover attempt May 6, laying out to investors its long-term revenue guidance forecasting $45 billion in revenues by 2023. Growth will be driven by a pipeline with $23 billion in peak sales potential.
You may also be interested in...
AstraZeneca will accelerate development of several mid-stage assets into Phase III and turn aggressively to business development under CEO Pascal Soriot’s strategy to transform the company, even as it shores up its P&L with more job cuts.
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.